Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

OGEN US Equity

Oragenics IncHealth Care · Pharmaceutical Preparations · CIK 1174940 · FY ends Dec 31
$0.55
+0.01 (+2.06%)
USD · as of 2026-08-18 · marketstack
3 registered studies · 1 active

Studies where OGEN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

3 interventional · 1 with posted results

Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 31.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240Patient symptom reportingQuadruple-masked · TreatmentPhase 2Not yet recruitingDrug: Neurosteroid enantiomerMild Traumatic Brain Injury, Concussion402026-01-012025-03-11
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per DayNCT03234465results2020-11-23Efficacy of AG013 Compared to Placebo for Reducing OM as Measured by Duration (in Days) of Severe Oral Mucositis (WHO Grades 3 or 4)Randomized · Quadruple-masked · TreatmentStudy Protocol · Statistical Analysis PlanPhase 2Terminatedsponsor's stated reason: No efficacy could be demonstrated, sponsor decided to prematurely end the study.Biological: AG013 · Other: PlaceboOral Mucositis2002020-03-31actual2020-11-23
Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)NCT01520974Enumeration of S. mutans in saliva and seven periodontal pathogens in subgingival plaqueRandomized · Triple-maskedNot applicableUnknown statusOther: ProBiora3 mints, Placebo tabletOral Health48Aug 20122012-05-02

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19